Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,209.28 +37.13 (+0.45%) Bitcoin USD
61,524.17 +2,165.05 (+3.65%) CMC Crypto 200
1,323.30 +46.32 (+3.63%)
Trevi Therapeutics, Inc. (TRVI)
| Previous close | 3.0100 |
| Open | 3.0200 |
| Bid | 3.0300 x 100 |
| Ask | 3.1000 x 200 |
| Day's range | 3.0110 - 3.1200 |
| 52-week range | 0.9700 - 4.0000 |
| Volume | |
| Avg. volume | 304,045 |
| Market cap | 212.08M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, May 7, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31,
- PR Newswire
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22. The presentation will take place on May 19th.
- PR Newswire
Trevi Therapeutics to Participate in Upcoming April Events
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will attend and participate in the following events in April.
